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Abstract
Syphilis is a sexually transmitted disease caused by the spirochete Treponema pallidum. 
It is transmissible by sexual contact, from mother to fetus, via blood transfusion, and 
occasionally by direct contact with infectious lesions. It has been a major public health 
problem both before the antibiotic era and now, with the increase of acquired immunode-
ficiency states and unprotected sex. The clinical manifestations of the disease can mimic 
many other infections and immune-mediated diseases; thus, it may be difficult to make 
early diagnosis. After the discovery of penicillin in the twentieth century, the spread of 
the disease has been largely controlled, but up to now, it has not been fully eradicated. In 
this chapter, overall information about the disease including the epidemiology, clinical 
presentation forms, pathophysiological mechanisms, and latest diagnostic and treatment 
approaches are reviewed.
Keywords: syphilis, clinical stages of syphilis, neurosyphilis, congenital syphilis, 
diagnosis of syphilis, treatment of syphilis
1. Introduction
Syphilis is an infectious sexually transmitted disease caused by the spirochete microorganism 
Treponema pallidum. Syphilis is transmissible by sexual contact with infectious lesions, from 
mother to fetus in utero, via blood product transfusion, and occasionally through breaks in 
the skin that come into contact with infectious lesions. Unprotected sex is the major risk factor 
for the acquisition of syphilis, especially among men who have sex with men (MSM). It is an 
intermittently active disease with primary, secondary, latent, and tertiary stages.
Syphilis is a disease with great historical importance and has played a major role in medicine 
for over a century. The disease was named after an afflicted shepherd named Syphilus in 1530. 
It is known to be “the great impostor,” particularly because the manifestations can mimic 
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many other infections and immune-mediated diseases. For this reason, the historical Sir 
William Osler once remarked “The physician who knows syphilis knows medicine.” Many 
famous people throughout the history are thought to have suffered from syphilis, including 
Bram Stoker, Henry VIII, and Vincent van Gogh. After the discovery of penicillin in the twen-
tieth century, the spread of the disease has been largely controlled, but up to now, it has not 
been fully eradicated.
The responsible microorganism T. pallidum is a fragile spiral bacterium. It can survive only 
briefly outside of the body; thus, transmission almost always requires direct contact with the 
infectious lesions. Incubation time from exposure to development of primary lesions, which 
occur at the primary site of inoculation, is approximately 3 weeks but can range from 10 to 
90 days. Regardless of the stage of disease and location of lesions, histopathologic hallmarks 
of syphilis include endarteritis and a plasma cell-rich infiltrate. Secondary syphilis develops 
about 4–10 weeks after the primary lesion. During this stage, the spirochetes multiply and 
spread throughout the body, and variable mucocutaneous lesions and systemic manifesta-
tions may be observed. During the secondary infection, the immune reaction is at its peak, 
and antibody titers are high.
Latent syphilis is a stage at which the features of secondary syphilis have subsided, but the 
patient is still seropositive. About one-third of untreated patients at this stage develop tertiary 
syphilis, whereas the rest remain asymptomatic. Tertiary syphilis is rather rare and mainly 
involves the cardiovascular and central nervous system, developing over months to years and 
involving slow inflammatory damage to tissues.
The morbidity of syphilis ranges from minor symptoms of the early stages to the more sig-
nificant systemic symptoms of secondary syphilis and neurological and cardiovascular conse-
quences of tertiary disease. Latent syphilis can persist for years, causing significant morbidity 
and mortality if left untreated. The prevalence of the disease continues to increase due to the 
emergence of the AIDS epidemic, since genital ulcers may facilitate the sexual transmission of 
HIV, and HIV-seropositive patients have an increased risk for rapid progression to neurosyph-
ilis. Approximately one-third of patients left untreated will develop late complications such as 
cardiovascular, neurosyphilis, or gummatous syphilis. Mortality rates are higher among these 
groups, up to 20% for tertiary syphilis, and late complications appear more commonly in men 
than in women [1]. On the other hand, for primary and secondary syphilis, the prognosis is 
rather good with appropriate treatment since T. pallidum is highly sensitive to penicillins.
2. Epidemiology
Syphilis is a worldwide-distributed disease and is particularly encountered in countries 
with low socioeconomic status. The rates of primary and secondary syphilis decreased dra-
matically worldwide with the introduction of penicillin treatment after the Second World 
War. It is estimated that worldwide in 2012, there were 18 million prevalent cases of syphilis 
in adolescents and adults aged 15–49 and 5.6 million new cases [2]. The global incidence 
rate was 1.5 cases per 1000 females and 1.5 cases per 1000 males. According to the same 
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report, the highest prevalence was in the African region, followed by the Southeast Asian 
and Western Pacific regions. In the United States, from 2005 to 2014, the overall number of 
reported primary and secondary syphilis cases increased significantly from 8724 to 19,999 
[3, 4]. In 2015, a total of 23,872 primary and secondary syphilis cases were reported, and 
the national rate increased by 19% to 7.5 cases per 100,000 population [5]. The rise in the 
rate of reported syphilis cases is primarily attributable to increased cases among men who 
have sex with men (MSM). The increasing incidence of syphilis in this population is due in 
part to rising rates of risky sexual behaviors, such as anonymous sex, unprotected sex (oral 
and anal), sex with multiple partners, and/or sex under the influence of drugs, especially 
methamphetamine. Concomitant HIV and syphilis infections are prevalent since they have 
similar modes of transmission, and infection with one may enhance the acquisition and 
transmission of the other among MSM. Available data suggest that approximately 50% of 
MSM with primary and secondary syphilis are HIV-infected, compared with 10% of men 
who have sex with women and 3.9% of women [6]. One long-term study conducted among 
US military personnel found that 5.8% of 4239 patients with newly diagnosed HIV infec-
tion also had serologic evidence of syphilis [7]. The rate of reported primary and secondary 
syphilis cases remains highest among Blacks, with the overall rate of syphilis being highest 
in Black men. As an example, in 2015, the rate of reported cases per 100,000 population was 
39.0 in Black men, 16.6 in Hispanic men, and 7.6 in White men. Similar ethnical percentages 
apply among women as well [5].
Congenital syphilis is also a significant public health problem, complicating an estimated 
one million pregnancies per year throughout the world [8]. The incidence of congenital 
syphilis reflects the rate of syphilis in women of childbearing age who received no prena-
tal care or treatment for syphilis before or during pregnancy. In the United States, the rate 
of congenital syphilis among infants <1 year of age fluctuated between 8 and 12 cases per 
100,000 live births between 2005 and 2015 [9]. The rate of congenital syphilis is increased 
among infants born to mothers with HIV infection. However, the contribution of maternal 
coinfection with syphilis and HIV to vertical transmission of either syphilis or HIV is not 
completely understood.
3. Pathophysiology
T. pallidum, the causative organism of syphilis, was first identified in 1905 by Schaudinn and 
Hoffmann [10]. It is a bacterium from the order Spirochaetales, a treponeme which causes 
human disease. T. pallidum is approximately 6–20 microns long and 0.1–0.18 microns in width, 
making it impossible to be visualized under direct light microscopy. With dark-field micros-
copy, casting an oblique light, T. pallidum is a corkscrew-shaped organism with wound spi-
rals. It exhibits a characteristic rotary motion with flexing and back-and-forth movement, all 
of which are considered to be diagnostic. It cannot survive outside an animal host, nor can it 
be cultured in vitro for extended time period.
The organism has lipid-rich outer membrane with uniform-sized transmembrane proteins 
and periplasmic flagella. Inoculation and penetration of the microorganism occur via mucosal 
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surfaces and abraded skin, followed by attachment to host cells and multiplication. Despite a 
slow estimated dividing time of 30 hours, the spirochete evades early host immune responses 
and establishes the initial ulcerative lesion, the chancre, disseminating to the regional lymph 
nodes and internal organs [11, 12].
3.1. Primary stage
The primary lesion develops 10–90 days after infection (3 weeks on average) as a papule, 
followed by necrosis and well-circumscribed ulceration that is firm to palpation (chancre), 
as well as enlarged regional lymph nodes. T. pallidum elicits innate and adaptive cellular 
immune responses in the skin and blood. At this stage, Th1-predominant cellular response 
with activation of macrophages is observed around the lesion [13]. Compared with periph-
eral blood, lesional fluids were enriched with CD4+ and CD8+ T cells, activated monocytes, 
macrophages, and dendritic cells. Many of these dendritic cells also express HIV coreceptors 
(e.g., CCR5 and DC-SIGN), which may help explain the epidemiologic link between syph-
ilis and HIV transmission [14]. Several pathogenic mechanisms including an antigenically 
inert treponemal cell surface, resistance to phagocytosis, and downregulation of the local 
host immune response have been considered for this stage. After acquisition of T. pallidum, 
humoral immune responses also lead to the development of a variety of antibodies, effectively 
providing the resolution of the primary chancre, even in the absence of therapy, while wide-
spread dissemination of spirochetes occurs at the same time, leading to subsequent clinical 
manifestations of secondary or tertiary syphilis.
3.2. Secondary stage
The secondary stage is characterized by dissemination and multiplication of the microorgan-
ism in different tissues in up to 6 months after the local lesion. This stage follows primary 
syphilis in almost every patient in the absence of appropriate treatment. Various lesions may 
occur due to circulating immune complexes, human fibronectin, antibodies, and comple-
ments with accompanying systemic signs [15].
3.3. Latency
Latency is the period between healing of the clinical lesions and appearance of late manifes-
tations, lasting for many years. Weakened immunity with aging may result in the reactiva-
tion of a small number of treponemes that had survived in sequestered sites. Alternatively, 
a partially immune hypersensitive host may react to the presence of treponemes, causing a 
chronic inflammatory response. About 70% of untreated individuals will remain in this stage 
for the rest of their lives and are immune to new primary infection. This period is divided into 
early (1 year or less) and late (more than 1 year) latency with positive serology for specific 
antibodies without clinical signs or symptoms. Infectivity may occur intermittently due to the 
presence of treponemes in the peripheral bloods, and thus pregnant women at this stage may 
infect the fetus in utero.
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3.4. Tertiary stage
At this stage the number of organisms decrease, but a high cellular immune response arises. 
Signs of late syphilis can be observed in approximately one-third of untreated individuals 
several months to years after being infected. The microorganisms may invade the central ner-
vous and cardiovascular systems as well as other organs characterized pathologically by the 
presence of granulomas, a result of delayed-type cellular hypersensitivity reaction. Studies 
with human subjects who were inoculated cutaneously with small numbers of live T. pallidum 
found that gummas developed only in those who had previous syphilis [16]. This suggests 
that development of gummas requires an immune response insufficient to be protective but 
substantial enough to cause tissue damage and granuloma formation in the reinfected host. 
Small vessel vasculitis is also a common manifestation of this stage with the presence of lym-
phocytes and plasma cells infiltrating blood vessels and perivascular tissues.
4. Clinical features
Syphilis is an intermittent disease with primary, secondary, and tertiary stages as well as 
a latent period of variable length, preceding the onset of tertiary syphilis. According to the 
Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), 
early syphilis includes the primary and secondary stages (CDC, acquired <1 year previ-
ously; WHO, acquired <2 years previously), and late syphilis extends from late latency (CDC, 
acquired >1 year previously; WHO, acquired >2 years previously) through the tertiary stage.
4.1. Primary syphilis
Following acquisition of T. pallidum, the chancre usually begins as a painless papule and pro-
gresses to a round or oval ulcer with raised and indurated margin. (Picture 1) The ulcer gen-
erally has a non-exudative base and is associated with mild to moderate regional, usually 
bilateral lymphadenopathy. The median incubation period before the chancre appears is 21 
days [17]. Untreated chancres heal in 3–6 weeks with the help of local immune responses. 
The lesions usually occur on the genitalia (Picture 2), but occasionally patients may develop 
chancres at other sites of inoculation. Cervical, anal, perianal, rectal, or posterior pharynx 
chancres may go unrecognized, and thus in these cases, syphilis is more frequently diag-
nosed during the secondary stage. The chancre represents an initial local infection, but syphi-
lis quickly becomes systemic with widespread dissemination of the spirochete. The presence 
of treponemes by dark-field microscopic examination of fluid from the surface of the chancre 
is the most sensitive and specific method for the diagnosis of primary syphilis. Cardiolipin, 
a component of mammalian cells, is modified by treponemes, and antibodies to cardiolipin 
can be measured by the rapid plasma reagin (RPR) or venereal disease research laboratory 
(VDRL) assay in about 80% of individuals at the onset of clinical symptoms. Alternatively, 
antibodies to surface proteins of T. pallidum detected by hemagglutination assays (T. pallidum 
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hemagglutination assay [TPHA], micro-hemagglutination assay for antibodies to T. pallidum 
[MHA-TP]) or fluorescent treponemal antibody absorption (FTA-ABS) assay are present in 
90% of patients with primary syphilis. Since antibodies usually remain positive for life, a dif-
ferentiation between primary syphilis and an earlier infection may not be possible, and dark-
field examination should be performed.
Picture 1. Primary syphilis chancre with indurated margin.
Picture 2. Syphilis chancre in subacute phase with crusts and desquamation.
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4.2. Secondary syphilis
The secondary stage of the disease results from the hematogenous and lymphatic dissem-
ination of treponemes in 3–10 weeks, observed in approximately 25% of individuals with 
untreated infection [18]. It is characterized by both mucocutaneous and systemic manifesta-
tions. Prodromal symptoms include fever, malaise, anorexia, sore throat, lymphadenopathy, 
weight loss, myalgia, and headache. These clinical manifestations probably reflect the immu-
nologic response resulting from widespread dissemination of T. pallidum.
Secondary syphilis has a vast variety of signs and symptoms. Most commonly encountered 
clinical presentation is generalized, non-pruritic papulosquamous eruption. The rash is very 
characteristic; however, in one series of 105 patients with secondary syphilis, more than 20% 
of the patients did not notice their lesions [19]. It is a diffuse, symmetric macular or papular 
eruption involving the entire trunk and extremities, including the palms and soles (Picture 3 
and 4). Involvement of the palms and soles is an important clue for the diagnosis of second-
ary syphilis [20]. Individual lesions are discrete copper, red, or reddish-brown and measure 
0.1–2 cm in diameter, with or without scales. (Picture 5) Pustular syphilis can be seen as small 
pustular syphilis, large pustular syphilis, flat pustular syphiloderm, or pustular-ulcerative 
syphilis. Superficial, painless aphthae-like lesions or gray plaques may be observed in mucosal 
areas. Large, raised, gray to white lesions called “condylomata lata” are often observed in the 
Picture 3. Symmetrical plantar eruptions of secondary stage syphilis.
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moist mucosal regions of the anogenital area or the mouth. These lesions occur most often in 
areas near to the primary chancre and may show direct spread of organisms from the primary 
ulcer. Malignant syphilis (lues maligna) is a rare entity with disseminated chancre-like lesions, 
particularly observed in case of immunodeficiency states such as AIDS [21]. Additional clinical 
findings include annular or figurate plaques with central hyperpigmentation on the face; non-
scarring and reversible “moth-eaten” alopecia on the scalp, eyebrows, or beard; granulomatous 
nodules and plaques, or crusted necrotic lesions. Lesions resolve over weeks to months without 
treatment, except for lues maligna. Occasionally, about 20% of untreated patients experience 
relapsing episodes of secondary syphilis, which can occur for up to 5 years after their initial 
infection.
Picture 4. Red to brownish papules on the extensor face of extremities, in secondary stage disease.
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Most patients with secondary syphilis have lymph node enlargement with palpable nodes 
present in the posterior cervical, axillary, inguinal, and femoral regions. Epitrochlear lymph-
adenopathy is particularly characteristic for the diagnosis. These nodes are generally mini-
mally tender, firm, and rubbery in consistency. Systemic findings of secondary syphilis 
include syphilitic hepatitis, extensive ulceration of gastrointestinal tract, synovitis, osteitis, 
periostitis, transient albuminuria, nephrotic syndrome, or acute nephritis with hypertension 
and acute renal failure [22, 23].
For the detection of secondary syphilis, dark-field examination of serous exudates from skin 
or mucosal lesions could be performed. On the other hand, serological tests are more useful at 
this stage. Cardiolipin and specific antibodies are always positive in patients with secondary 
Picture 5. Brown to purple macules and papules, scattered in flexor or extensor face of distal extremities.
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syphilis, except for a temporary negative non-treponemal test in case of prozone phenom-
enon or HIV infection.
4.3. Latent syphilis
After a period of 3–12 weeks, untreated secondary syphilis typically resolves spontaneously, 
followed by an asymptomatic state called latent syphilis. The diagnosis at this stage can only 
be made based on a positive serology. About 90% of relapses occur within the first year, 
referred as early latent stage. After 1 year, the patients enter the late latent stage, lasting for 
months to years.
About one-third of infected individuals have a nonreactive RPR test and no reactivation 
for the rest of their lives, and only the specific antibody assays (e.g., MHA-TP, FTA-ABS) 
remain positive. For another one-third of patients, antibodies against cardiolipin (e.g., RPR, 
VDRL) persist together with a positive MHA-TP or FTA-ABS assay without any symptoms. 
The remaining one-third, however, progresses to tertiary syphilis. For the cases without any 
medical history regarding the presence of clinical symptoms in the past weeks or months and 
previous treatments, differentiation between early and late latency is not possible. This group 
of patients is accepted as having late latent syphilis. This distinction is particularly important 
because patients with late latent disease are not considered infectious to their recent sexual 
contacts since they do not have lesions that can transmit disease. In contrast, patients with 
early latent syphilis may have transmitted T. pallidum to their sexual partners through lesions 
that were recently active, but are no longer present. Differentiating early from late latent dis-
ease also has implications for treatment approaches. Response of latent syphilis to treatment 
is indicated by a decline in the RPR or VDRL titer.
4.4. Tertiary (late) syphilis
Approximately 25–40% of patients with untreated syphilis can develop late disease, and 
symptoms may appear at any time from 1 to 30 years after primary infection [24]. Tertiary 
syphilis has a variable range of manifestations that appear months to years after initial infec-
tion. Involvement of the skin, bones, CNS, heart, and major vessels is pathognomonic. Half of 
the patients with tertiary syphilis develop only gummatous lesions, while the remaining have 
either cardiovascular disease or neurological manifestations. A confirmed case of late syphilis 
with clinical manifestations requires the demonstration of T. pallidum in late syphilitic lesions 
by special stains, polymerase chain reaction, or equivalent direct molecular methods. A prob-
able case is diagnosed when characteristic abnormalities or lesions are noted along with a 
reactive treponemal serological test. All patients with a suspicion of tertiary syphilis should 
undergo lumbar puncture and CSF examination for detection of neurosyphilis.
4.4.1. Gummatous syphilis
The most common feature of late syphilis is gummas, which are locally destructive lesions 
in the skin, bones, liver, and other organs. The gummas in the skin are nodular or noduloul-
cerative granulomatous lesions with a round, irregular, or serpiginous shape, remaining for 
Fundamentals of Sexually Transmitted Infections116
weeks to months, and eventually heal with scar tissue. A subcutaneous gumma may become 
necrotic, resulting in ulceration of the skin or mucous membranes as well as destruction of 
underlying bones. Gummatous lesions of the bones are usually accompanied by periostitis 
and osteitis. Clinical manifestations include pain, swelling, and limited range of motion. 
Other sites that can be affected by gummas include the tongue and oral cavity, upper respira-
tory tract, myocardium, and gastrointestinal and nervous systems.
4.4.2. Cardiovascular syphilis
Cardiovascular syphilis has a late onset, with a latent period of 15–30 years. During the early 
stage of the disease, vasa vasorum of the proximal aorta is affected, and transmural inflamma-
tory lesions leading to endarteritis of the vessels develop. The disease typically involves the 
ascending thoracic aorta resulting in dilatation and aortic valve regurgitation. Vasculitis of the 
vasa vasorum leads to weakening of the wall of the aortic root [25]. The onset is insidious, and 
most patients present with an asymptomatic murmur or with left heart failure. Syphilis may 
also involve the coronary arteries, resulting in narrowing and thrombosis.
4.4.3. Neurosyphilis
Neurosyphilis is the infection of the central nervous system by T. pallidum, and although it 
is typically a manifestation of tertiary syphilis, it can occur at any stage of the disease. It was 
common in the pre-antibiotic era, occurring in 25–35% of patients with syphilis; however, 
nowadays, it is most frequently seen in patients with HIV infection [26–28]. Within this group 
of patients, lower peripheral CD4+ T cell counts are closely linked to have symptomatic neu-
rosyphilis [29]. Early in the course, the disease involves cerebrospinal fluid, meninges, and 
vasculature, while later on brain and spinal cord parenchyma are also affected.
4.4.3.1. Early neurosyphilis
The disease process begins with the invasion of the cerebrospinal fluid; however, this does 
not always result in persistent infection, and spontaneous resolution may occur after tran-
sient meningitis. Failure to clear organisms from the CSF results in “asymptomatic neuro-
syphilis,” and individuals with this form of neurosyphilis are at risk for subsequent forms 
of symptomatic neurosyphilis [30]. The diagnosis of asymptomatic neurosyphilis is based 
on the identification of CSF abnormalities, including a lymphocytic pleocytosis, elevated 
protein concentration, and a reactive CSF-VDRL. Patients with asymptomatic neurosyphilis, 
regardless of CSF-VDRL reactivity, should be treated for neurosyphilis to prevent progres-
sion to symptomatic disease. Symptomatic meningitis occurs mostly within the first year after 
infection, and patients may have headache, confusion, nausea and vomiting, and stiff neck. 
Visual acuity may be impaired if there is concomitant uveitis, vitritis, retinitis, or optic neu-
ropathy. The CSF abnormalities are more severe than those seen in asymptomatic meningitis. 
Cerebrovascular syphilis is, on the other hand, an infarction secondary to syphilitic endarteri-
tis, which can result in hemiparesis or hemiplegia. This form of neurosyphilis may present as 
an ischemic stroke in a young person.
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4.4.3.2. Late neurosyphilis
Parenchymatous neurosyphilis is observed at this stage, which is due to the direct invasion of 
the cerebrum by treponemes. General paresis and tabes dorsalis are the hallmarks of late neu-
rosyphilis, and if untreated it can progress to death. General paresis (paretic neurosyphilis) 
is a progressive condition, usually developing 10–25 years after the infection. Initial findings 
include deficits in memory, judgment, and personality changes, and severe dementia may be 
seen in progression [31]. Common abnormal neurological findings include dysarthria; facial 
and limb hypotonia; intentional tremors of the face, tongue, and hands; and reflex abnormali-
ties. Tabes dorsalis is a disease of the posterior columns of the spinal cord and dorsal roots. It 
has the longest latent period between primary infection and onset of symptoms with the inter-
val averaging about 20 years. Most frequent symptoms are sensory ataxia and lancinating 
pains, which are sudden pain attacks affecting the limbs, back, or face. Pupillary irregularities 
are among the most common signs in patients with tabes dorsalis, and the Argyll Robertson 
pupil accounts for approximately half of these. Diplopia, loss of vibratory and position sense, 
reduced reflexes in the legs, ataxia, and sphincter dysfunction are other symptoms of tabes 
dorsalis.
In patients with known syphilis, a lumbar puncture with CSF examination should be per-
formed if neurologic or ophthalmic signs or symptoms appear in any stage of the disease, if 
there is evidence of active tertiary syphilis affecting other parts of the body, and if there is a 
treatment failure including the failure of serum non-treponemal tests to fall appropriately. In 
addition to the clinical findings, the diagnosis of neurosyphilis is based upon reactive blood 
and CSF serologies, which are almost always positive with elevation of pressure, protein con-
centration, and immunoglobulin levels as well as a mononuclear pleocytosis. The presence 
of specific antitreponemal antibodies in the CSF is mandatory, but the specificity is low since 
IgG antibodies can diffuse into the CSF or result from contamination of the CSF by blood. 
CSF to serum IgG ratio divided by CSF to serum albumin ratio gives the CSF-IgG index, and 
a value of greater than 0.7 indicates IgG synthesis in the brain due to local inflammation. The 
presence of nonspecific antibodies, e.g., a positive VDRL test or RPR assay in CSF, is observed 
in most cases.
4.5. Congenital syphilis
Congenital syphilis occurs when the spirochete T. pallidum is transmitted from a pregnant 
woman to her fetus. Infection can result in stillbirth, prematurity, or a wide spectrum of clini-
cal manifestations, and only severe cases are clinically apparent at birth. If a child has physi-
cal, laboratory, or radiographic signs of congenital syphilis and was born to a mother with 
untreated, inadequately, or suboptimally treated syphilis, this condition is defined as con-
genital syphilis. It is a significant public health problem, complicating an estimated one mil-
lion pregnancies per year throughout the world [8]. Most cases develop because the mother 
received no prenatal care or treatment for syphilis before or during pregnancy. Among 
women with untreated early syphilis, 40% of pregnancies result in spontaneous abortion [32]. 
Congenital syphilis is generally acquired through transplacental transmission of spirochetes 
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in the maternal bloodstream or, occasionally, through direct contact with an infectious lesion 
during birth [33].
4.5.1. Early congenital syphilis
Infants generally present with symptoms during the neonatal period or within the first 3 
months of life. Typical manifestations are cachexia and skin lesions similar to those of acquired 
secondary syphilis. Bloody or purulent mucinous nasal discharge, perioral and perianal fis-
sures, anemia, thrombocytopenia, syphilitic pneumonitis, hepatitis, nephropathy, lymphade-
nopathy, and hepatosplenomegaly may also be observed. Osteochondritis of skeletal bones 
may result in pseudoparalysis of Parrot due to reduced movement of the extremities due to 
pain.
4.5.2. Late congenital syphilis
This clinical entity of childhood or adolescent period corresponds to tertiary syphilis in adults. 
In about one-third of children, an interstitial keratitis is seen; this finding together with typical 
dental abnormalities (Hutchinson’s teeth) and neural deafness forms the Hutchinson triad.
The initial evaluation for congenital syphilis in infants and children should include a quanti-
tative VDRL or RPR titer, physical examination for evidence of congenital syphilis, dark-field 
microscopic examination or direct fluorescent antibody staining of suspicious lesions or body 
fluids, and, for newborns, pathologic examination of the placenta and umbilical cord with 
specific fluorescent antitreponemal antibody staining. IgG antibodies which are present in 
the bloodstream of the child may have been acquired transplacentally from the mother. A 
serum titer for a non-treponemal test that is fourfold higher than the mother’s titer is sugges-
tive of infection, but infected neonates may have lower titers. FTA-ABS-19S-IgM test to detect 
19S-antibodies and IgM-capture ELISA test have high sensitivity for these cases. Additionally, 
detection of spirochetemia by PCR can improve the sensitivity of the diagnosis of congenital 
syphilis in neonates. In late congenital syphilis, diagnosis is based on clinical findings in asso-
ciation with reactive serologic tests.
5. Syphilis and pregnancy
Syphilis remains an important health concern for women at childbearing age. Failure to 
detect or adequately treat maternal disease often results in serious consequences for the 
fetus. Clinical features and diagnostic approaches are similar to normal population. All preg-
nant women should be screened for syphilis at the first prenatal visit, and the test should be 
repeated during the third trimester (28–32 weeks of gestation) and again at delivery in women 
who are at high risk for syphilis. Vertical transmission of syphilis can occur at any time dur-
ing pregnancy and at any stage of the disease. Treatment of maternal syphilis at least 30 
days before delivery is the most important factor influencing the risk of congenital infection. 
Penicillin remains the gold standard for the treatment of syphilis in pregnant patients as well. 
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Penicillin desensitization is indicated for infected pregnant women with documented penicil-
lin allergy as alternative drugs are not as safe or effective as penicillin.
6. Syphilis and HIV
Genital ulcerative diseases, such as syphilis, can increase the risk of both sexual and perina-
tal HIV transmission [34]. This is mostly because of the lack of an epithelial barrier due to 
ulceration of the skin or mucous membranes, large numbers of macrophages and T cells with 
receptors for HIV, and production of cytokines by macrophages stimulated by treponemal 
lipoproteins. Patients with HIV are at increased risk for neurosyphilis, especially if they have 
a CD4 count <350 cells/ml and/or a RPR titer of ≥1:32; however, unless neurologic symptoms 
are present, CSF examination in HIV patients has not been associated with improved clinical 
outcomes [35]. Clinical manifestations of syphilis and treatment approaches are similar for 
HIV-infected and HIV-noninfected patients; however, serologic responses appear slower in 
these patient groups.
7. Workup and laboratory diagnosis
Patients presenting with suspicious signs and symptoms of syphilis, pregnant women, com-
mercial sex workers, sexually active men who have sex with men, and HIV-infected indi-
viduals should be routinely screened for syphilis. All patients with positive syphilis serology 
should also be tested for HIV infection.
The diagnosis of syphilis is based on the direct detection of treponemes or treponemal DNA by 
microscopy or molecular biologic techniques as well as various serologic tests. There are two 
types of serologic tests for syphilis: against cardiolipin (non-treponemal tests) antigens and 
treponemal antigens (treponemal tests). These tests rely upon a humoral immune response to 
infection. Thus, the use of serologic testing may be limited in patients with advanced immu-
nosuppression or early disease.
7.1. Direct detection of T. pallidum
T. pallidum cannot be routinely cultured in vitro; thus, microscopic examination or molecu-
lar assays are used to detect the microorganism directly. With careful collection of serous 
fluid containing specimens, movement of spirochetes can be visualized by dark-field micros-
copy. Direct fluorescent antibody (DFA) testing can be also used to detect the organism; how-
ever, neither of these complex tests is routinely performed nor available in clinical settings. 
Alternatively, some laboratories have developed polymerase chain reaction (PCR)-based 
assays to detect T. pallidum DNA target sequences from clinical specimens. According to vari-
ous studies, the sensitivity and specificity of PCR method from lesional specimens are rela-
tively high, up to 95 and 98%, respectively [36–40]. However, PCR tests are not suitable for 
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screening asymptomatic individuals, since the sensitivity of PCR testing tends to be much 
lower in blood and cerebrospinal fluid specimens (approximately 24–32%) [36].
7.2. Non-treponemal tests
They are based upon the reactivity of serum from infected patients to a cardiolipin-choles-
terol-lecithin antigen and include venereal disease research laboratory (VDRL), rapid plasma 
regain (RPR), unheated serum reagin (USR), reagin screen test (RST), and toluidine red 
unheated serum test (TRUST). All these tests measure IgG and IgM antibodies against this 
lipoprotein-like material released from damaged host cells and treponemes. Titers of these 
antibodies correlate with disease activity and are used for screening and monitoring the treat-
ment. These quantitative tests are performed even in case of a positive dark-field examina-
tion, to obtain a baseline for the follow-up of the treatment process. A fourfold decrease in 
the antibody titer indicates successful treatment, while a fourfold increase indicates relapse 
or reinfection. In the case of early and efficacious treatment, non-treponemal assays usually 
become negative over time. Although these screening tests are nonspecific, and therefore not 
definitive, they have traditionally been used for initial syphilis screening due to their rela-
tively low cost and ease of performance.
7.3. Treponemal tests
The major indication for treponemal tests is confirmation of reactive non-treponemal tests. 
However, nowadays, they have been automated, with fast and easy use, and as a result, these 
tests are increasingly used as an initial screening test rather than as confirmatory tests. They 
are based upon the detection of antibodies directed against specific treponemal antigens and 
thus tend to be more specific than non-treponemal tests. The sensitivity varies with the stage 
of syphilis: between 70 and 100% in primary syphilis, 100% in secondary and latent syphilis, 
and about 95% in late syphilis [41]. Treponemal tests are qualitative only and are reported as 
“reactive” or “nonreactive.” These tests cannot differentiate between antibodies to T. pallidum 
and other treponemes or spirochetes, and they generally remain positive for lifetime; thus, 
they are not used for monitoring the response to treatment.
T. pallidum hemagglutination assay (TPHA), micro-hemagglutination assay for T. pallidum 
(MHA-TP), and T. pallidum particle agglutination (TPPA) tests: these tests measure antibod-
ies directed against surface proteins of T. pallidum attached to rabbit erythrocytes as anti-
gen carriers. Positive result shows previous or active syphilis but disease activity cannot be 
determined.
Fluorescent treponemal antibody absorption (FTA-ABS): This test shows the reaction of 
serum and whole treponeme and forming of antigen-antibody complexes with the help of 
fluorescein isothiocyanate. IgM and IgG can be selectively differentiated.
FTA-ABS-19S-IgM test: Fraction of IgM antibody is measured, with a higher specificity. This 
test is used for differentiation of relapsing disease from reinfection or in case of congenital 
syphilis.
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Solid-phase hemadsorption assay (SPHA) or IgM ELISA: This test is used for the detection 
of specific IgM antibodies that attach to the solid phase of microtiter plates by reacting with 
the treponemal antigen on rabbit erythrocytes as antigen carriers. IgM antibodies can also be 
measured by the ELISA technology. They are used for the diagnosis of congenital syphilis, 
neurosyphilis, and reinfection.
T. pallidum enzyme immunoassay (TP-EIA)
In late 2014, the US Food and Drug Administration granted a Clinical Laboratory Improvement 
Amendments waiver permitting the use of a rapid (10-minute) finger-stick treponemal-based 
antibody test called the Syphilis Health Check (SHC) [42]. But exact sensitivity and specific-
ity of this test have not been established yet. In Table 1 types and different properties of both 
treponemal and non-treponemal tests are summarized.
Serologic testing to diagnose syphilis should include the use of both non-treponemal and 
treponemal tests [43]. Traditional serologic testing algorithms for syphilis involve initial 
screening with a non-treponemal test. A reactive result is then confirmed with a treponemal 
test, such as FTA-ABS. If the non-treponemal test is negative and patient is asymptomatic, 
no further testing is necessary. If both tests are reactive and the patient has no history of 
previous disease, the results are consistent with a new infection, and appropriate treatment 
should be prompted. However, for patients with a history of treated syphilis in the past with 
positive treponemal and non-treponemal results, the need for treatment depends upon the 
patient’s clinic and the non-treponemal titer. This may indicate a new infection, an evolving 
response to recent treatment, treatment failure, or the presence of a serofast state. In case of 
a new infection, non-treponemal test reveals a fourfold or greater increase in titer from the 
individual’s prior posttreatment test. If the patient has persistently reactive but low titer 
Treponemal tests Non-treponemal tests
• Treponema pallidum 
hemagglutination assay 
(TPHA)
• Micro-hemagglutination 
assay for Treponema pal-
lidum (MHA-TP)
• T. pallidum particle 
agglutination assay 
(TPPA)
• Fluorescent treponemal 
antibody absorption 
(FTA-ABS)
• FTA-ABS-19S-IgM test
• Solid-phase hemadsorp-
tion assay (SPHA)
• IgM ELISA
• T. pallidum enzyme 
immunoassay (TP-EIA)
• Possible false negativity 
in early-stage disease
• May remain positive for 
lifetime
• Not useful for monitor-
ing treatment response
• Possible false positivity 
(autoimmune diseases, 
HIV infection, hyper-
gammaglobulinemia)
• High sensitivity and 
specificity
• Venereal disease 
research laboratory 
(VDRL)
• Rapid plasma 
regain (RPR)
• Unheated serum 
reagin (USR)
• Reagin screen test 
(RST)
• Toluidine red 
unheated serum 
test (TRUST)
• Possible false negativity in 
early-stage disease
• Useful for monitoring 
treatment response
• May become negative with 
early treatment
• Possible false negativity 
(prozone phenomenon, 
HIV)
• Possible false positivity 
(pregnancy, autoim-
mune diseases, drug use, 
lymphomas, malaria, 
vaccinations, cirrho-
sis, antiphospholipid 
syndrome)
• Low cost and ease of 
performance
Table 1. Serological tests for diagnosis of syphilis.
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non-treponemal test despite adequate treatment, it is considered as a serofast state. All other 
cases are regarded as treatment failures and should be retreated properly.
Alternatively, a popular novel approach uses treponemal tests such as TP-EIA as a screening 
method, followed by a non-treponemal test for confirmation. With this reverse order, there 
is an increase in false positivity rates but also an increase likelihood of catching patients with 
very early or late latent syphilis.
In case of a positive but usually low titer non-treponemal test followed by a negative one dur-
ing screening, the patient is generally considered to have a false-positive syphilis result. It is 
estimated that 1–2% of the United States population has false-positive non-treponemal test 
results [44]. False-positive tests may be observed during pregnancy, acute febrile illness such 
as endocarditis or rickettsial disease, recent immunization, autoimmune disorders (particu-
larly systemic lupus erythematosus), intravenous drug use, chronic liver disease, and in case 
of HIV disease [41].
If the patient has a positive treponemal and negative non-treponemal test, clinical symptoms 
should be investigated, and treatment should be administered in case of a positive finding. 
However, if there are no clinical signs or symptoms and repeated treponemal test is also posi-
tive, treatment for late latent syphilis is recommended. Another possibility is false-positive 
treponemal test which can be seen in case of spirochetal infections, malaria, and leprosy [45].
Negative non-treponemal test together with possible clinical signs and symptoms may point 
out early syphilis, prior to antibody formation or can be due to prozone effect [46]. In such 
cases of early primary syphilis, fluorescent treponemal antibody absorption (FTA-ABS) is 
thought to be the most sensitive method. Prozone reaction is also a major cause of a false-neg-
ative non-treponemal test. High titers of antibodies, usually in secondary syphilis, interfere 
with clumping of antigen-antibody complexes and make the visualization of the agglutina-
tion impossible. This phenomenon is usually associated with pregnancy, HIV coinfection, 
and neurosyphilis [47].
8. Pathology
Ulceration and dermal infiltrate of plasma cells, lymphocytes, and histiocytes are observed 
in primary syphilis. Spirochetes may also be detected with Warthin-Starry stain. In case of 
secondary syphilis, dermal infiltrates can be perivascular, lichenoid, diffuse, or nodular, with 
necrotic or ulcerated epidermis. In tertiary syphilis, tuberculoid granulomas, endothelial 
swelling, and vascular proliferation are present together with plasma cells.
9. Differential diagnosis
For primary syphilis, all conditions causing genital ulcers should be taken into consideration. 
These most commonly include genital herpes, chancroid, lymphogranuloma venereum, 
Behçet’s disease, and fixed drug eruption. In case of secondary syphilis, cutaneous findings may 
resemble viral exanthems, guttate psoriasis, pityriasis rosea, lichen planus, pityriasis lichenoides 
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chronica, maculopapular drug eruptions, or nonspecific nummular eczema. Recurrent aphthous 
stomatitis, oral lichen planus, herpangina, candidiasis, and hand,foot, and mouth disease should 
be considered in case of mucosal involvement. Genital mucosa findings of secondary stage may 
mimic HPV-related lesions such as condyloma lata, bowenoid papulosis, or squamous cell carci-
noma. Gummatous lesions of tertiary syphilis can be mistaken for lupus vulgaris, leishmaniasis, 
deep fungal infections, mycosis fungoides, and sarcoidosis.
10. Treatment
A non-treponemal serologic test should be obtained before initiating therapy (preferably 
on the first day of treatment) to establish the pretreatment titer and adequacy of serological 
response. Parenteral penicillin G is the treatment of choice for all stages of the disease [16, 43, 
48]. A penicillin level of >0.018 mcg/l is considered treponemicidal, and this level of antimi-
crobial should be present in serum and/or CSF [49]. The dosage and duration of treatment 
depend upon the stage of the disease. For patients without neurosyphilis, penicillin G benza-
thine is the preferred formulation, and it is given via intramuscular route. In case of penicillin 
allergy, rechallenging or desensitization can be tried initially. Alternative antimicrobial agents 
include tetracyclines and cephalosporins. Azithromycin should be used only if other agents 
are not available, because treatment failures due to macrolide-resistant T. pallidum have been 
reported [50, 51]. The CDC and International Union against Sexually Transmitted Infections 
(IUSTI) currently recommend that HIV-infected individuals receive the same syphilis regi-
mens as HIV-negative patients. Stage of the disease and treatment options are summarized 
in Table 2.
10.1. Early syphilis
The goals of treatment are to prevent long-term adverse outcomes and reduce transmission. A 
diagnosis of early syphilis implies that T. pallidum infection occurred within the previous year 
and consists of primary, secondary, and early latent syphilis. A single dose of 2.4 million units of 
penicillin G benzathine (intramuscular) is the standard therapy for early syphilis [48, 50, 52]. No 
resistance against penicillin G has been reported up to now, and clinical cure rates are 90 to 100% 
for both HIV-uninfected and HIV-infected persons. First-line alternative to penicillin is doxycy-
cline (100 mg PO twice daily), for 14 days. Oral amoxicillin (3 g) with probenecid (500 mg) can 
also be used, twice daily for 14 days. One to two grams of parenteral ceftriaxone for 10–14 days 
and a single 2 g dose of azithromycin are other alternatives [53–55]. Jarisch-Herxheimer reaction 
is an acute febrile reaction frequently accompanied by headache and myalgias within the first 24 
hours of penicillin treatment and is most common among patients with early syphilis.
10.2. Late syphilis
This includes tertiary and late latent syphilis, with longer duration of treatment. Penicillin G 
benzathine (2.4 million units intramuscularly) once weekly for three weeks is the standard 
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therapy for late syphilis [43]. If the patient misses a dose or more than 14 days have elapsed 
since the prior dose, the course should be reinitiated [56]. Patients with gummatous or cardio-
vascular infection should have a CSF examination prior to therapy to assess for neurosyphilis.
Administration of 40–60 mg of prednisolone daily for 3 days beginning 24 hours before treat-
ment for any form of cardiovascular syphilis may be advised [57]. Alternative regimens for 
late syphilis include doxycycline (100 mg PO twice daily for 28 days) or ceftriaxone (2 g IV or 
IM daily for 10–14 days); however, as there are limited data on the efficacy of these regimens 
in late syphilis, close monitoring is mandatory [58].
Clinical stage Recommended treatment 
regimen
Alternative treatment regimen
Early syphilis • Primary
• Secondary
• Early latent (acquired <1 
year previously)
• Penicillin G benzathine 
2.4 million units IM, 
single dose
• Procaine penicillin, 1.2 mil-
lion units, for 10 days
• Doxycycline 100 mg orally 
twice daily for 14 days
• Ceftriaxone 1–2 g daily IM or 
IV for 10–14 days
• Tetracycline 500 mg orally 
four times daily for 14 days
• Azithromycin, 2 g orally, 
single dose
• Amoxicillin 3 g plus pro-
benecid 500 mg, orally twice 
daily for 14 days
Late syphilis • Late latent (acquired >1 year 
previously or of unknown 
duration)
• Cardiovascular and gum-
matous syphilis
• Retreatment of primary, 
secondary, or latent syphilis 
after treatment failure
• Penicillin G benzathine 
2.4 million units IM 
once weekly for 3 
weeks
• Procaine penicillin, 1.2 mil-
lion units IM for 20 days
• Doxycycline 100 mg orally 
twice daily for 28 days
• Ceftriaxone 2 g daily IM or 
IV for 10–14 days
• Tetracycline, 500 mg orally 
for 28 days
Neurosyphilis • Early neurosyphilis
• Late neurosyphilis
• Penicillin G 3–4 million 
units IV every 4 hours 
(18–24 million units by 
continuous infusion) 
for 10–14 days
• Penicillin G procaine 
2.4 million units IM 
daily plus probenecid 
500 mg orally four 
times daily, for 10–14 
days
• If possible, patients allergic 
to penicillin should be 
desensitized and treated 
with IV penicillin
• Ceftriaxone, 2 g IM or IV for 
10–14 days
Table 2. Stage of the disease and treatment options.
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10.3. Neurosyphilis
These patients should generally be treated with intravenous therapy due to the fact that 
higher doses are necessary to produce measurable cerebrospinal fluid levels of the drug [59]. 
Preferred regimen is IV penicillin G (3–4 million units IV every 4 hours or 18–24 million units 
per day by continuous infusion) for 10–14 days. If the patient has late syphilis, together with 
neurosyphilis, a single dose or three doses of penicillin G benzathine (2.4 million units IM) 
may be administered after this course of therapy, for longer duration of effect. If the patient 
is allergic to penicillin, desensitization or rechallenge is strongly advised, so that the standard 
IV regimen can be used instead of an alternative regimen. Procaine penicillin plus proben-
ecid, ceftriaxone, oral amoxicillin with probenecid, or doxycycline are other alternatives with 
limited success rates.
11. Follow-up
Patients should be monitored clinically and with laboratory testing to ensure that they are 
responding appropriately to therapy. A fourfold decline in the non-treponemal titer, equiva-
lent to a change of two dilutions, is considered as good response to therapy. In a systematic 
review that included data from 20 studies, a fourfold or greater decline in non-treponemal 
titers was associated with younger age, higher baseline non-treponemal titers, and earlier 
syphilis stage [60].
If non-treponemal titers do not decline fourfold or if there is a fourfold increase after initial 
decline, this is considered as treatment failure. Since drug resistance to penicillin has not been 
described, treatment failure is likely due to poor adherence with the treatment regimen, treat-
ment with an alternative agent, immunocompromised status, or undiagnosed neurosyphilis. 
It is also important to distinguish this treatment failure from reinfection.
In patients with early syphilis, serologic testing should be performed 6 and 12 months follow-
ing treatment and at any time if clinical symptoms recur. Patients with late syphilis should 
undergo follow-up serologic testing at 6, 12, and 24 months. In case of abnormal CSF findings, 
a CSF examination is recommended at a 6-month interval until cell counts are normal and the 
CSF-VDRL is negative.
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